

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/5/05

Signature: *GINNY BUNDALL*

(Ginny Bundall)



Docket No.: APBI-P05-035
(PATENT)

1636
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Baltimore et al.

Application No.: 10/037341

Confirmation No.: 6591

Filed: January 4, 2002

Art Unit: 1636

For: NUCLEAR FACTORS ASSOCIATED WITH
TRANSCRIPTIONAL REGULATION

Examiner: Not Yet Assigned

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed from the Patent Office on December 8, 2004, a copy of which is attached.

Transmitted herewith is a copy of a Substitute Sequence Listing in paper form (sheets 1/20 through 20/20) comprising SEQ ID NOS: 1-60 for the above-identified patent application as required by 37 C.F.R. 1.825(a) and 1.821(c), and a copy of the Substitute Sequence Listing in computer readable form as required by 37 C.F.R. 1.825(b) and 1.821(e). Please replace the Sequence Listing filed on February 19, 2004, sheets 1/19 through 19/19 with the attached Substitute Sequence Listing.

As required by 37 C.F.R. 1.825(b), Applicants' Attorney hereby states that the contents of the Substitute Sequence Listing in paper form and in the computer readable form submitted

herewith are the same and, as required by 37 C.F.R. 1.825(a), also states that the submission includes no new matter.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. APBI-P05-035 from which the undersigned is authorized to draw.

Dated: January 5, 2005

Respectfully submitted,

By 

Melissa S. Rones, Ph.D.

Registration No.: 54,408

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624


(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/037,341	01/04/2002	David Baltimore	APBI-P05-035

CONFIRMATION NO. 6591

FORMALITIES LETTER



OC000000014695118

28120
 ROPES & GRAY LLP
 ONE INTERNATIONAL PLACE
 BOSTON, MA 02110-2624

Date Mailed: 12/08/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>
- For Patent Software Program Help, call (571) 272-2510 or email mark.spencer@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

A handwritten signature in black ink, consisting of a stylized 'G' followed by a horizontal line and a loop.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

OIPE ROUTING SHEET APPLICATION



10/037,341

TO BE DELIVERED TO:

O I P E

CP2-6C17

LOCA 0380

Sequence Rule Compliance Review Item

	CRF, paper copy of sequence listing, and statement that both are same missing
	CRF contains error(s) according to STIC Report
	CRF damaged or unreadable according to STIC Report
	CRF transferred from prior application is not compliant
X	Sequences missing from Sequence Listing

Place an "X" in the appropriate box

A handwritten signature in black ink, appearing to read "Remy Yucel".

REMY YUCEL, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

APPLICATION SERIAL NUMBER

10/037,341



**DOES NOT COMPLY WITH THE
SEQUENCE RULES. See reasons below.**

Nucleotide and amino acid sequences present on pages 27 and 86 of the specification and in Figure 18A(Cont.) have not been included in the Sequence Listing.